Felix Frueh

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.

Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE.

Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.

Ariana Pharmaceuticals SA provides pharmaceutical, clinical and data technology. It offers analytics for multi-paramedic data in identifying patient responders to reduce clinical and drug development risk. The firm also develops biomarker signatures to develop processes in anawlyzing multi-paramedic data. The company was founded by Mohammad Afshar in 2003 and is headquartered in Paris, France.

Profound Ventures LLC solves profound societal problems. It engaged in creating, seed funding, and growing new business ventures and non-profit organizations to solve. The company was founded by Felix Frueh and Brian Meshkin and is headquartered in Newport Beach, CA.

Selva Therapeutics, Inc. is a privately held biotechnology company that is dedicated to developing therapeutics for infectious diseases. The company is based in Del Mar, CA. The company's main focus is on rapidly developing SLV213 for COVID-19, which has the potential to fight multiple life-threatening infectious diseases. Selva Therapeutics was founded by Thomas E. Daley and Felix Wilhelm Frueh, and Thomas E. Daley has been the CEO since incorporation.